Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

253.99 -8.68 (-3.30%)
Streaming Delayed Price Updated: 10:22 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,884
Open 261.51
Bid (Size) 252.61 (200)
Ask (Size) 255.72 (100)
Prev. Close 262.67
Today's Range 252.61 - 264.02
52wk Range 122.80 - 298.30
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism ↗
Jefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Krystal Biotech (KRYS) Q4 2025 Earnings Transcript ↗
Krystal Biotech (KRYS) Q4 2025 Earnings Transcript 
Via The Motley Fool

Performance

YTD
+2.9%
+2.9%
1 Month
-7.6%
-7.6%
3 Month
+24.4%
+24.4%
6 Month
+74.3%
+74.3%
1 Year
+44.2%
+44.2%

More News

Read More
Krystal Biotech Inc (NASDAQ:KRYS) Reports Q4 2025 Earnings Beat and Key Pipeline Advancements ↗
Via Chartmill
Topics Earnings
News headline image
Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
Via The Motley Fool
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
Via The Motley Fool
News headline image
Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund Has an $8.5 Million Bet on Five9 Despite a 50% One-Year Stock Collapse ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗
Via Benzinga
News headline image
Krystal Biotech (KRYS) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Krystal Biotech (KRYS) Q3 2025 Earnings Top Estimates on Strong VYJUVEK Sales ↗
Via Chartmill
News headline image
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts ↗
Via Benzinga
News headline image
$100 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Insider Confidence Shines: Krystal Biotech and Growth Stocks with Strong Management Stakes Navigate Volatile Markets
Via MarketMinute
Topics Artificial Intelligence World Trade
News headline image
What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗
Via Benzinga
News headline image
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗
Via Benzinga

Frequently Asked Questions

Is Krystal Biotech, Inc. - Common Stock publicly traded?
Yes, Krystal Biotech, Inc. - Common Stock is publicly traded.
What exchange does Krystal Biotech, Inc. - Common Stock trade on?
Krystal Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Krystal Biotech, Inc. - Common Stock?
The ticker symbol for Krystal Biotech, Inc. - Common Stock is KRYS on the Nasdaq Stock Market
What is the current price of Krystal Biotech, Inc. - Common Stock?
The current price of Krystal Biotech, Inc. - Common Stock is 253.99
When was Krystal Biotech, Inc. - Common Stock last traded?
The last trade of Krystal Biotech, Inc. - Common Stock was at 02/20/26 10:22 AM ET
What is the market capitalization of Krystal Biotech, Inc. - Common Stock?
The market capitalization of Krystal Biotech, Inc. - Common Stock is 5.64B
How many shares of Krystal Biotech, Inc. - Common Stock are outstanding?
Krystal Biotech, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.